In biology, a negative result can sometimes be surprisingly valuable. A paper may test a gene, decide it is not part of the pathway under study, and in doing so provide unusually credible evidence that the gene’s protein product exists in the experimental system. That is exactly the case for GPRC6A in the bovine mammary epithelial cell paper:
“Taurine Promotes Milk Synthesis via the GPR87-PI3K-SETD1A Signaling in BMECs.”
The paper was authored by Mengmeng Yu, Yang Wang, Zhe Wang, Yanxu Liu, Yang Yu, and Xuejun Gao, with affiliations at Agricultural College of Guangdong Ocean University and The Key Laboratory of Dairy Science of Education Ministry, Northeast Agricultural University. It was published in the Journal of Agricultural and Food Chemistry in 2019, volume 67, pages 1927 to 1936, DOI 10.1021/acs.jafc.8b06532.
The headline conclusion of the paper is not about GPRC6A. The authors conclude that taurine promotes milk synthesis through GPR87-PI3K-SETD1A signaling. In the abstract, they state that gene-function approaches revealed GPR87-PI3K-SETD1A signaling was required for taurine to increase mTOR and SREBP-1c mRNA levels, and that taurine stimulated GPR87 expression and membrane localization.
But this is precisely why the GPRC6A result is interesting.
The authors did not build their story around GPRC6A. They tested GPRC6A as a plausible candidate receptor, knocked it down, found that taurine signaling still occurred, and then moved the pathway to GPR87. That makes the GPRC6A Western blot evidence less likely to be a pathway-confirmation artifact. The GPRC6A band was not needed to sell the final mechanism. In fact, the final mechanism explicitly excludes GPRC6A from taurine signaling.
Why GPRC6A was tested at all
The authors had a strong biological reason to consider GPRC6A. In the introduction, they explain that some GPCRs can sense extracellular amino acids and activate downstream signaling such as PI3K/mTOR. They specifically name GPRC6A as one of these amino-acid-sensing GPCRs.
They also state in the Results that previous mass-spectrometric data showed both GPRC6A and GPR87 were upregulated in BMECs treated with methionine. Therefore, they hypothesized that GPRC6A, GPR87, or both might be required for taurine-induced PI3K activation.
This gives the experiment a clean logic:
Taurine activates PI3K. GPRC6A and GPR87 are candidate GPCRs. Knock each down. See which one matters.
The key assay: Western blot detection of GPRC6A protein
The paper’s Methods section lists a specific antibody for GPRC6A detection: GPRC6A antibody ab138994 from Abcam. The same Western blot workflow also used antibodies against GPR87, SETD1A, H3K4Me3, PI3K pathway proteins, mTOR, SREBP-1c, and β-actin. The signals were visualized by chemiluminescence, quantified in ImageJ, and normalized to β-actin or histone H3.
This matters because the paper is not only mentioning GPRC6A in text. It directly measures a GPRC6A protein band by Western blot.
The strongest GPRC6A evidence: siRNA knockdown in Figure 7A
The crucial figure is Figure 7A.
In Figure 7A, BMECs were transfected with GPRC6A siRNA and treated with 0.24 mM taurine for 24 hours. The figure caption explicitly states that cells were transfected with GPRC6A siRNA and then analyzed by Western blot.
The Methods section gives the exact GPRC6A siRNA sequence used:
GPRC6A-siRNA: 5′-GCUCUGAGGUGUGUUUCUATT-3′.
This is important because the experiment is not simply “we saw a band and named it GPRC6A.” The authors used a targeted knockdown reagent against GPRC6A and then observed the Western blot signal under knockdown conditions.
That provides two layers of evidence:
- Baseline detection: a GPRC6A protein band is detectable in bovine mammary epithelial cells.
- Knockdown validation: the GPRC6A band is reduced after GPRC6A siRNA treatment.
This makes the protein-level evidence much stronger than a standalone antibody blot. A Western blot band that decreases after gene-specific siRNA behaves like the intended protein signal. It is not perfect proof, but it is one of the more persuasive practical validations used in cell-biology papers.
What Figure 7A actually shows
Figure 7A tests whether GPRC6A is required for taurine-induced PI3K activation.
The result is beautifully paradoxical for our purpose.
The authors report that GPRC6A knockdown did not suppress PI3K activation after taurine stimulation. In their interpretation, this means GPRC6A is not required for taurine to activate PI3K.
So Figure 7A says two things at once:
First: GPRC6A protein is detectable and knockdown-able in bovine BMECs.
Second: GPRC6A is not the receptor responsible for taurine-to-PI3K signaling.
That distinction is the whole treasure chest.
If the authors wanted to force a GPRC6A pathway story, Figure 7A would have been inconvenient. Instead, they used it to eliminate GPRC6A and support GPR87.
Why the negative result makes the GPRC6A blot more credible
One has to be careful here: we cannot know the authors’ intentions. But we can evaluate the evidentiary structure.
The GPRC6A Western blot is not being used to claim that GPRC6A mediates taurine signaling. The paper’s main pathway is GPR87, not GPRC6A. The Results section states that GPRC6A knockdown did not block taurine-induced PI3K activation, while GPR87 knockdown largely abolished taurine effects on p-PI3K, p-mTOR, and SREBP-1c.
The Discussion says this even more directly: “GPR87 but not GPRC6A” knockdown abolished taurine’s stimulatory effects on PI3K and downstream signaling.
That makes the GPRC6A detection valuable in a special way. The authors had no pathway-level incentive to exaggerate GPRC6A as functional in taurine signaling, because their conclusion goes the other way. Yet they still show a GPRC6A Western blot band and use GPRC6A siRNA in Figure 7A.
In other words, the GPRC6A signal is not decorative confetti thrown over the main claim. It is part of a receptor-exclusion experiment.
The contrast with GPR87 sharpens the argument
The paper’s positive receptor is GPR87.
In Figure 7B to 7F, GPR87 knockdown reduces GPR87 protein and blocks taurine-induced p-PI3K, p-mTOR, and SREBP-1c responses. The figure caption describes the GPR87 knockdown Western blots and quantification of GPR87, p-PI3K/PI3K, p-mTOR/mTOR, and SREBP-1c.
That contrast matters.
The authors did not merely say, “GPRC6A exists.” They ran a comparative receptor screen:
GPRC6A knockdown: taurine signaling survives.
GPR87 knockdown: taurine signaling collapses.
This makes the GPRC6A experiment a clean negative control against the GPR87 result.
But for protein existence, the GPRC6A portion remains valuable because it demonstrates that the GPRC6A protein signal was measurable and experimentally reducible in bovine cells.
What this paper can honestly be used to claim
This paper should not be cited as evidence that GPRC6A mediates taurine-induced milk synthesis. It says the opposite.
But it can be cited as strong evidence for this narrower claim:
Bovine mammary epithelial cells contain a detectable GPRC6A protein signal by Western blot, and this signal is reduced by GPRC6A-targeting siRNA.
That is a meaningful protein-level validation.
The strongest honest wording would be:
Yu et al. tested GPRC6A as a candidate taurine receptor in bovine mammary epithelial cells. Although GPRC6A knockdown did not block taurine-induced PI3K activation, Figure 7A provides protein-level evidence that GPRC6A is detectable by Western blot in BMECs and that the detected signal is responsive to GPRC6A siRNA knockdown. Thus, the paper is negative evidence for GPRC6A in taurine signaling, but positive evidence for the existence of GPRC6A protein in cow mammary epithelial cells.
Why this matters for bovine GPRC6A functionality
Functional annotation often asks several different questions:
- Is the gene present in the genome?
- Is the transcript expressed?
- Is the protein product detectable?
- Is the protein part of a biological pathway?
- Is it required for a particular phenotype?
This taurine paper helps mainly with question 3.
It does not show that GPRC6A mediates taurine signaling. It does not establish direct ligand binding. It does not prove a GPRC6A-dependent taurine phenotype. But it does show a GPRC6A protein band in bovine BMECs and a targeted knockdown experiment that reduces the band.
For the broader cow GPRC6A argument, this paper should be used as a brick, not the whole barn.
Together with other bovine papers where GPRC6A knockdown blocks lysine or palmitic-acid signaling, this taurine paper adds an independent piece of evidence: even in a pathway where GPRC6A is ruled out, the protein is still detected and experimentally manipulated.
That is why this paper is useful. Not because it makes GPRC6A the taurine receptor, but because it shows that GPRC6A was present enough, measurable enough, and knockdown-able enough to be tested and rejected.
Final interpretation
The most honest conclusion is:
This paper provides strong evidence for the existence of GPRC6A protein in bovine mammary epithelial cells, based on Western blot detection and siRNA knockdown validation in Figure 7A. However, it does not support GPRC6A as part of the taurine-induced milk-synthesis pathway. Instead, the authors use the GPRC6A knockdown result to exclude it and identify GPR87 as the functional taurine-responsive receptor.
That is not a weakness. It is exactly why the GPRC6A protein evidence is persuasive.
The paper clears GPRC6A from the taurine pathway, but in doing so, it leaves behind a useful fingerprint: GPRC6A protein exists in cow mammary epithelial cells and can be detected by Western blot. 🐄